Literature DB >> 17672444

C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols.

Demetris P Papahatjis1, Victoria R Nahmias, Spyros P Nikas, Thanos Andreou, Shakiru O Alapafuja, Andrew Tsotinis, Jianxin Guo, Pusheng Fan, Alexandros Makriyannis.   

Abstract

In earlier work we have provided evidence for the presence of a subsite within the CB1 and CB2 cannabinoid receptor binding domains of classical cannabinoids. This putative subsite corresponds to substituents on the C1'-position of the C3-alkyl side chain, a key pharmacophoric feature in this class of compounds. We have now refined this work through the synthesis of additional C1'-cycloalkyl compounds using newly developed approaches. Our findings indicate that the C1'-cyclopropyl and C1'-cyclopentyl groups are optimal pharmacophores for both receptors while the C1'-cyclobutyl group interacts optimally with CB1 but not with CB2. The C1'-cyclohexyl analogs have reduced affinities for both CB1 and CB2. However, these affinities are significantly improved with the introduction of a C2'-C3' cis double bond that modifies the available conformational space within the side chain and allows for a better accommodation of a six-membered ring within the side chain subsite. Our SAR results are highlighted by molecular modeling of key analogs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17672444     DOI: 10.1021/jm070121a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.

Authors:  Spyros P Nikas; Shakiru O Alapafuja; Ioannis Papanastasiou; Carol A Paronis; Vidyanand G Shukla; Demetris P Papahatjis; Anna L Bowman; Aneetha Halikhedkar; Xiuwen Han; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

2.  Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids.

Authors:  Demetris P Papahatjis; Victoria R Nahmias; Spyros P Nikas; Marion Schimpgen; Alexandros Makriyannis
Journal:  Chemistry       Date:  2010-04-06       Impact factor: 5.236

3.  AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.

Authors:  Torbjörn U C Järbe; Sherrica Tai; Brian J LeMay; Spyros P Nikas; Vidyanand G Shukla; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

4.  2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective.

Authors:  Alexandros Makriyannis
Journal:  J Med Chem       Date:  2014-05-01       Impact factor: 7.446

5.  Synthesis and characterization of a compact tricyclic resorcinol from (+)- and (-)-3-pinanol.

Authors:  Dai Lu; Spyros P Nikas; Xiu-Wen Han; Damon A Parrish; Alexandros Makriyannis
Journal:  Tetrahedron Lett       Date:  2012-08-29       Impact factor: 2.415

6.  C-ring cannabinoid lactones: a novel cannabinergic chemotype.

Authors:  Rishi Sharma; Spyros P Nikas; Jason Jianxin Guo; Srikrishnan Mallipeddi; JodiAnne T Wood; Alexandros Makriyannis
Journal:  ACS Med Chem Lett       Date:  2014-01-14       Impact factor: 4.345

7.  Controlled-deactivation cannabinergic ligands.

Authors:  Rishi Sharma; Spyros P Nikas; Carol A Paronis; Jodianne T Wood; Aneetha Halikhedkar; Jason Jianxin Guo; Ganesh A Thakur; Shashank Kulkarni; Othman Benchama; Jimit Girish Raghav; Roger S Gifford; Torbjörn U C Järbe; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-12-10       Impact factor: 7.446

8.  Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands.

Authors:  Dai Lu; Jianxin Guo; Richard I Duclos; Anna L Bowman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2008-10-01       Impact factor: 7.446

9.  Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.

Authors:  William A Kinney; Mark E McDonnell; Hua Marlon Zhong; Chaomin Liu; Lanyi Yang; Wei Ling; Tao Qian; Yu Chen; Zhijie Cai; Dean Petkanas; Douglas E Brenneman
Journal:  ACS Med Chem Lett       Date:  2016-02-10       Impact factor: 4.345

10.  Sulfonyl fluoride inhibitors of fatty acid amide hydrolase.

Authors:  Shakiru O Alapafuja; Spyros P Nikas; Indu T Bharathan; Vidyanand G Shukla; Mahmoud L Nasr; Anna L Bowman; Nikolai Zvonok; Jing Li; Xiaomeng Shi; John R Engen; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2012-11-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.